女性与间歇性跛行血管腔内及开放干预后再干预更多相关
基于血管质量倡议(VQI)2010—2020年数据,纳入间歇性跛行(IC)行外周血管腔内干预(PVI)、腹股沟下旁路(IIB)及腹股沟上旁路(SIB)的患者,比较性别与结局。女性术前指南推荐药物治疗比例较低,1年免再干预生存率在三种干预后均低于男性,多变量分析证实女性与1年再干预增加相关;截肢-free生存与生存率无差异。
要点
- 女性IC患者PVI、IIB、SIB术前阿司匹林及他汀使用比例均低于男性(P<0.05)。
- 女性PVI、IIB、SIB后1年免再干预生存率均低于男性。
- 多变量分析显示女性与1年再干预增加独立相关(PVI HR 1.16,IIB HR 1.16,SIB HR 1.60)。
核心结论
- 女性IC患者术前药物治疗优化比例略低于男性,且女性与干预后再干预增加相关。
- 作者建议治疗女性患者的干预医师应加强最大化药物治疗的努力。
- 作者提出未来研究应阐明女性患者干预耐久性较差的原因。
研究设计与样本
- 回顾性队列研究,查询血管质量倡议(VQI)2010—2020年因任何程度IC行PVI、IIB及SIB的患者。
- PVI女性24,701例、男性40,051例;IIB女性2,789例、男性6,525例;SIB女性1,695例、男性2,370例。
- 采用单变量和多变量分析比较围手术期及长期结局。
主要发现
- 女性PVI术前阿司匹林73.4% vs 男性77.3%,IIB 71.5% vs 74.8%,SIB 70.9% vs 74.3%(均P<0.05)。
- 女性PVI术前他汀71.8% vs 男性76.7%,IIB 73.1% vs 76.0%(均P<0.05)。
- 女性PVI后1年免再干预生存率84.4%±0.3% vs 男性86.3%±0.2%(P<0.001)。
- 女性IIB后1年免再干预生存率79.0%±0.9% vs 男性81.2%±0.6%(P=0.04)。
- 女性SIB后1年免再干预生存率89.4%±0.9% vs 男性92.6%±0.7%(P=0.005)。
关键数值与推荐
- 多变量分析:女性与PVI后1年再干预相关(HR 1.16,95%CI 1.09-1.24,P<0.001)。
- 多变量分析:女性与IIB后1年再干预相关(HR 1.16,95%CI 1.03-1.31,P=0.02)。
- 多变量分析:女性与SIB后1年再干预相关(HR 1.60,95%CI 1.20-2.13,P=0.001)。
- 所有干预后截肢-free生存与生存率在女性与男性间相似。
临床怎么用
- 作者建议治疗女性IC患者的干预医师应加强最大化药物治疗的努力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intermittent claudication (IC) is a commonly treated vascular condition. Patient sex has been shown to influence outcomes of interventions for other vascular disorders; however, whether outcomes of interventions for IC vary by sex is unclear. We sought to assess the association of patient sex with outcomes after IC interventions. METHODS: The Vascular Quality Initiative was queried from 2010-2020 for all peripheral endovascular interventions (PVI), infra-inguinal bypasses (IIB), and supra-inguinal bypasses (SIB) for any degree IC. Univariable and multivariable analyses compared peri-operative and long-term outcomes by patient sex. RESULTS: There were 24,701 female and 40,051 male patients undergoing PVI, 2,789 female and 6,525 male patients undergoing IIB, and 1,695 female and 2,370 male patients undergoing SIB for IC. Guideline-recommended pre-operative medical therapy differed with female patients less often prescribed aspirin for PVI (73.4% vs. 77.3%), IIB (71.5% vs. 74.8%), and SIB (70.9% vs. 74.3%) or statins for PVI (71.8% vs. 76.7%) and IIB (73.1% vs. 76.0%) (all P < 0.05). Female compared with male patients had lower 1-year reintervention-free survival after PVI (84.4% ± 0.3% vs. 86.3% ± 0.2%, P < 0.001), IIB (79.0% ± 0.9% vs. 81.2% ± 0.6%, P = 0.04), and SIB (89.4% ± 0.9% vs. 92.6% ± 0.7%, P = 0.005), but similar amputation-free survival and survival across all procedures. Multivariable analysis confirmed that female sex was associated with increased 1-year reintervention for PVI (HR 1.16, 95% CI 1.09-1.24, P < 0.001), IIB, (HR 1.16, 95% CI 1.03-1.31, P = 0.02), and SIB (HR 1.60, 95% CI 1.20-2.13, P = 0.001). CONCLUSIONS: Female patients undergoing interventions for IC were less often pre-operatively medically optimized than male patients, though the difference was small. Furthermore, female sex was associated with more reinterventions after interventions. Interventionists treating female patients should increase their efforts to maximize medical therapy. Future research should clarify reasons for poorer intervention durability in female patients.
引用
- Levin SR, Farber A, King EG, et al. Female Sex is Associated with More Reinterventions after Endovascular and Open Interventions for Intermittent Claudication. Ann Vasc Surg. 2022. PMID: 35809741. doi:10.1016/j.avsg.2022.05.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。